Correspondence with both Dr Joseph H. Burchenal and Dr Cornelius P. Rhoads both of the Sloan-Kettering Institute for Cancer Research, New York regarding the use of 6-mercaptopurine in the treatment of patients with leukaemia with comments on its effectiveness, dosage, and long-term use. Wilkinson is also sent some supplies of the drug. Rhoads then follows up on this to get information from Wilkinson about his experience with the drug so that general experiences in clinical trials can be drawn together.
Included in the file is a detailed report on the history and chemistry, toxicity, clinical indications, dosage, and precautions relating to 'Purinethol' brand 6-mercaptopurine produced by Burroughs Wellcome & Co. There are also a number of blank forms provided for writing up case reports. There is also an extract of the Sloan-Kettering Institute for Cancer Research Progress Report from May 1953 and a report entitled 'Summary of Clinical Experience with 6-Mercaptopurine of the Chemotherapy Service of Memorial Center, New York'.